New hope for Hard-to-Treat cancers: experimental drug targets KRAS mutation
NCT ID NCT06383871
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called HRS-7058 in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study aims to find the safest dose and see if the drug can shrink tumors or slow their growth. About 233 participants will receive the drug in capsule or tablet form.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-7058 (a drug targeting the KRAS G12C mutation)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced cancers that have a specific KRAS G12C mutation.
- What could go wrong
- This is an early Phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. The drug may not work or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOUR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.